MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine JournalGlobeNewsWire • 02/28/22
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in DrugsGlobeNewsWire • 02/22/22
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in KoreaGlobeNewsWire • 02/01/22
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in CanadaGlobeNewsWire • 01/31/22
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in EuropeGlobeNewsWire • 01/27/22
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in EuropeGlobeNewsWire • 01/26/22
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALSGlobeNewsWire • 12/13/21
MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MNDGlobeNewsWire • 12/10/21
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-OncologyGlobeNewsWire • 11/22/21
MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver DiseasesGlobeNewsWire • 11/11/21
MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science MeetingGlobeNewsWire • 11/10/21
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-OncologyGlobeNewsWire • 11/03/21
MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)GlobeNewsWire • 10/21/21
MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare ConferenceGlobeNewsWire • 09/03/21
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver DiseasesGlobeNewsWire • 09/01/21
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MNDGlobeNewsWire • 08/30/21
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic DiseaseGlobeNewsWire • 07/06/21
MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare ConferenceGlobeNewsWire • 06/29/21
MediciNova To Test Ibudilast In BARDA's Validated Mouse Model Of Chlorine-Induced Pulmonary InjuryBenzinga • 06/28/21
MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryGlobeNewsWire • 06/28/21